Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report
Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - NHS Quality Improvement Scotland
Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - GlaxoSmithKline
Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - Professor Allan Price
Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - Royal College of Nursing
This page was last updated: 30 March 2010